Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

PAK4 pathway as a potential therapeutic target in pancreatic cancer.

Thillai K, Sarker D, Wells C.

Future Oncol. 2018 Mar;14(7):579-582. doi: 10.2217/fon-2017-0458. Epub 2018 Mar 6. No abstract available.

2.

Regorafenib as treatment for patients with advanced hepatocellular cancer.

Thillai K, Srikandarajah K, Ross P.

Future Oncol. 2017 Oct;13(25):2223-2232. doi: 10.2217/fon-2017-0204. Epub 2017 Aug 2.

PMID:
28766967
3.

PAK4 interacts with p85 alpha: implications for pancreatic cancer cell migration.

King H, Thillai K, Whale A, Arumugam P, Eldaly H, Kocher HM, Wells CM.

Sci Rep. 2017 Feb 16;7:42575. doi: 10.1038/srep42575.

4.

Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?

Thillai K, Lam H, Sarker D, Wells CM.

Oncotarget. 2017 Feb 21;8(8):14173-14191. doi: 10.18632/oncotarget.13309. Review.

5.

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.

Ziogas DC, Papadatos-Pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O'Grady J, Al-Khadimi G, Allen N, Heaton N, Ross PJ, Sarker D.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):48-55.

PMID:
27623000
6.

Clinical outcomes for patients with liver-limited metastatic colorectal cancer: Arguing the case for specialist hepatobiliary multidisciplinary assessment.

Thillai K, Repana D, Korantzis I, Kane P, Prachalias A, Ross P.

Eur J Surg Oncol. 2016 Sep;42(9):1331-6. doi: 10.1016/j.ejso.2016.03.031. Epub 2016 Apr 19.

PMID:
27174600
7.

Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?

Thillai K, Ross P, Sarker D.

World J Gastrointest Oncol. 2016 Feb 15;8(2):173-85. doi: 10.4251/wjgo.v8.i2.173. Review.

8.

A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration.

Al-Mahdi R, Babteen N, Thillai K, Holt M, Johansen B, Wetting HL, Seternes OM, Wells CM.

Cell Adh Migr. 2015;9(6):483-94. doi: 10.1080/19336918.2015.1112485.

9.

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG.

Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185.

10.

FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.

Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D.

Expert Rev Anticancer Ther. 2014 Oct;14(10):1115-25. doi: 10.1586/14737140.2014.957188. Epub 2014 Sep 10. Review.

PMID:
25204327
11.

Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer.

Adjogatse D, Thanopoulou E, Okines A, Thillai K, Tasker F, Johnston SR, Harper-Wynne C, Torrisi E, Ring A.

Clin Oncol (R Coll Radiol). 2014 Nov;26(11):692-6. doi: 10.1016/j.clon.2014.05.002. Epub 2014 Jun 6.

PMID:
24909701
12.

Observation as a treatment strategy for advanced renal cell carcinoma-a call for prospective validation.

Fisher R, Pender A, Thillai K, Chowdhury S, Pickering L, Khabra K, Gore M, Larkin J.

Front Oncol. 2012 Oct 31;2:155. doi: 10.3389/fonc.2012.00155. eCollection 2012. No abstract available.

13.

Neoadjuvant and adjuvant treatment of renal cell carcinoma.

Thillai K, Allan S, Powles T, Rudman S, Chowdhury S.

Expert Rev Anticancer Ther. 2012 Jun;12(6):765-76. doi: 10.1586/era.12.56. Review.

PMID:
22716493

Supplemental Content

Loading ...
Support Center